Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Kidney Cancer | Research

SIRT5 functions as a tumor suppressor in renal cell carcinoma by reversing the Warburg effect

Authors: Liu Yihan, Wang Xiaojing, Liu Ao, Zhang Chuanjie, Wang Haofei, Shen Yan, He Hongchao

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

The aim of this study was to investigate the biological functions and underlying mechanisms of SIRT5 in clear cell renal cell carcinoma (ccRCC).

Methods

SIRT5 expression data in The Cancer Genome Atlas Kidney Clear Cell Carcinoma (TCGA-KIRC) were selected, and the correlations between SIRT5 expression and various clinicopathological parameters were analysed. SIRT5 expression in ccRCC tissues was examined using immunohistochemistry. Stable cell lines with SIRT5 knockdown were established. In vitro and in vivo experiments were conducted to investigate the functional roles of SIRT5 in the cellular biology of ccRCC, including cell viability assays, wound healing assays, soft agar colony formation assays, Transwell invasion assays, qRT–PCR, and Western blotting. In addition, microarrays, rescue experiments and Western blotting were used to investigate the molecular mechanisms underlying SIRT5 functions.

Results

SIRT5 expression was downregulated in ccRCC compared with normal tissues, which correlated with a poor prognosis of ccRCC. SIRT5 knockdown significantly increased cell proliferation, migration and invasion in vitro. In vivo experiments revealed that SIRT5 knockdown promoted ccRCC tumorigenesis and metastasis. Mechanistically, SIRT5 deglycosylated PDHA1 at K351 and increased PDC activity, thereby altering the metabolic crosstalk with the TCA cycle and inhibiting the Warburg effect. SIRT5 overexpression was related to low succinylation of PDHA1.

Conclusions

Downregulated SIRT5 expression in ccRCC accelerated the Warburg effect through PDHA1 hypersuccinylation and induced tumorigenesis and progression, indicating that SIRT5 may become a potential target for ccRCC therapy.
Literature
1.
go back to reference Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–24.CrossRef Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–24.CrossRef
2.
go back to reference Hakimi AA, et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial. Cancer Discov. 2019;9(4):510–25.CrossRef Hakimi AA, et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial. Cancer Discov. 2019;9(4):510–25.CrossRef
3.
go back to reference Mitchell TJ, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173(3):611-623 e17.CrossRef Mitchell TJ, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173(3):611-623 e17.CrossRef
4.
go back to reference Ljungberg B, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.CrossRef Ljungberg B, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.CrossRef
5.
go back to reference Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23(1):27–47.CrossRef Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23(1):27–47.CrossRef
6.
go back to reference Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.CrossRef Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.CrossRef
7.
go back to reference Bowker-Kinley MM, et al. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998;329:191–6.CrossRef Bowker-Kinley MM, et al. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998;329:191–6.CrossRef
8.
go back to reference Patel MS, Korotchkina LG. Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp Mol Med. 2001;33(4):191–7.CrossRef Patel MS, Korotchkina LG. Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp Mol Med. 2001;33(4):191–7.CrossRef
9.
go back to reference CaJacob CA, Gavino GR, Frey PA. Pyruvate dehydrogenase complex of Escherichia coli thiamin pyrophosphate and NADH-dependent hydrolysis of acetyl-CoA. J Biol Chem. 1985;260(27):14610–5.CrossRef CaJacob CA, Gavino GR, Frey PA. Pyruvate dehydrogenase complex of Escherichia coli thiamin pyrophosphate and NADH-dependent hydrolysis of acetyl-CoA. J Biol Chem. 1985;260(27):14610–5.CrossRef
10.
go back to reference Kolobova E, et al. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J. 2001;358:69–77.CrossRef Kolobova E, et al. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J. 2001;358:69–77.CrossRef
11.
go back to reference Kato M, et al. Structural basis for inactivation of the human pyruvate dehydrogenase complex by phosphorylation_role of disordered phosphorylation loops. Structure. 2008;16:1849–59.CrossRef Kato M, et al. Structural basis for inactivation of the human pyruvate dehydrogenase complex by phosphorylation_role of disordered phosphorylation loops. Structure. 2008;16:1849–59.CrossRef
12.
go back to reference Korotchkina LG, Patel MS. Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites. J Biol Chem. 2001;276(8):5731–8.CrossRef Korotchkina LG, Patel MS. Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites. J Biol Chem. 2001;276(8):5731–8.CrossRef
13.
go back to reference Ciszak EM, et al. Structural basis for flip-flop action of thiamin pyrophosphate-dependent enzymes revealed by human pyruvate dehydrogenase. J Biol Chem. 2003;278(23):21240–6.CrossRef Ciszak EM, et al. Structural basis for flip-flop action of thiamin pyrophosphate-dependent enzymes revealed by human pyruvate dehydrogenase. J Biol Chem. 2003;278(23):21240–6.CrossRef
14.
go back to reference Sutendra G, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell. 2014;158:84–97.CrossRef Sutendra G, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell. 2014;158:84–97.CrossRef
15.
go back to reference Shi YG. Serine/threonine phosphatases_ mechanism through structure. Cell. 2009;139:468–84.CrossRef Shi YG. Serine/threonine phosphatases_ mechanism through structure. Cell. 2009;139:468–84.CrossRef
16.
go back to reference Li XL, Kazgan N. Mammalian sirtuins and energy metabolism. Int J Biol Sci. 2011;7:575–87.CrossRef Li XL, Kazgan N. Mammalian sirtuins and energy metabolism. Int J Biol Sci. 2011;7:575–87.CrossRef
17.
go back to reference Rardin MJ, et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab. 2013;18:920–33.CrossRef Rardin MJ, et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab. 2013;18:920–33.CrossRef
18.
go back to reference Du JT, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011;334(6057):806–9.CrossRef Du JT, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011;334(6057):806–9.CrossRef
20.
go back to reference Park J, et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell. 2013;50:919–30.CrossRef Park J, et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell. 2013;50:919–30.CrossRef
21.
go back to reference Fan J, et al. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell. 2014;53:534–48.CrossRef Fan J, et al. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell. 2014;53:534–48.CrossRef
22.
go back to reference Jing EX, et al. Sirt3 regulate metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes. 2013;63:3404–17.CrossRef Jing EX, et al. Sirt3 regulate metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes. 2013;63:3404–17.CrossRef
23.
go back to reference Mathias RA, et al. Sirtuin 4 Is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell. 2014;159:1615–25.CrossRef Mathias RA, et al. Sirtuin 4 Is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell. 2014;159:1615–25.CrossRef
24.
go back to reference Li F, et al. NADP+-IDH mutations promote hypersuccinylation that impairs mitochondria respiration and induces apoptosis resistance. Mol Cell. 2015;60:661–75.CrossRef Li F, et al. NADP+-IDH mutations promote hypersuccinylation that impairs mitochondria respiration and induces apoptosis resistance. Mol Cell. 2015;60:661–75.CrossRef
25.
go back to reference Hannahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRef Hannahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRef
26.
go back to reference Tan MJ, et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 2014;19:605–17.CrossRef Tan MJ, et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 2014;19:605–17.CrossRef
27.
go back to reference Yuya N, et al. SIRT5 regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target. Mol Cell. 2015;59:321–32.CrossRef Yuya N, et al. SIRT5 regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target. Mol Cell. 2015;59:321–32.CrossRef
28.
go back to reference He XD, et al. Sensing and transmitting intracellular amino acid signals through reversible lysine aminoacylations. Cell Metab. 2018;27:1–16.CrossRef He XD, et al. Sensing and transmitting intracellular amino acid signals through reversible lysine aminoacylations. Cell Metab. 2018;27:1–16.CrossRef
29.
go back to reference Nakamura Y, et al. SIRT5 deacetylates and activates urate oxidase in liver mitochondria of mice. FEBS Lett. 2012;586:4076–81.CrossRef Nakamura Y, et al. SIRT5 deacetylates and activates urate oxidase in liver mitochondria of mice. FEBS Lett. 2012;586:4076–81.CrossRef
30.
go back to reference Lin ZF, et al. SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem Biophys Res Commun. 2013;441:191–5.CrossRef Lin ZF, et al. SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem Biophys Res Commun. 2013;441:191–5.CrossRef
31.
go back to reference Wang F, et al. SIRT5 desuccinylates and activates pyruvate kinase M2 to block macrophage IL-1β production and to prevent DSS-induced colitis in mice. Cell Rep. 2017;19:2331–44.CrossRef Wang F, et al. SIRT5 desuccinylates and activates pyruvate kinase M2 to block macrophage IL-1β production and to prevent DSS-induced colitis in mice. Cell Rep. 2017;19:2331–44.CrossRef
32.
go back to reference Yang X, et al. SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. Cancer Res. 2018;78(2):372–86.CrossRef Yang X, et al. SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. Cancer Res. 2018;78(2):372–86.CrossRef
33.
go back to reference Park J, et al. Human melanoma cell need SIRT5 to survive. Free Radic Biol Med. 2016;100:S128.CrossRef Park J, et al. Human melanoma cell need SIRT5 to survive. Free Radic Biol Med. 2016;100:S128.CrossRef
34.
go back to reference Ou T, et al. SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching. Clin Transl Med. 2020;10(5):e172.CrossRef Ou T, et al. SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching. Clin Transl Med. 2020;10(5):e172.CrossRef
35.
go back to reference Di Emidio G, et al. Mitochondrial sirtuins in reproduction. Antioxidants (Basel). 2021;10(7):1047.CrossRef Di Emidio G, et al. Mitochondrial sirtuins in reproduction. Antioxidants (Basel). 2021;10(7):1047.CrossRef
Metadata
Title
SIRT5 functions as a tumor suppressor in renal cell carcinoma by reversing the Warburg effect
Authors
Liu Yihan
Wang Xiaojing
Liu Ao
Zhang Chuanjie
Wang Haofei
Shen Yan
He Hongchao
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03178-6

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.